{
    "nctId": "NCT01777958",
    "briefTitle": "HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy",
    "officialTitle": "Noninterventional Study - Advanced HER2-positive Breast Cancer (Metastatic or Locally Recurrent, Inoperable): First-Line Treatment With PERJETA After Adjuvant Herceptin Therapy (HELENA)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 135,
    "primaryOutcomeMeasure": "Median progression-free survival in routine clinical practice",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female adult patients, \\>/= 18 years of age\n* HER2-positive advanced breast cancer (metastatic or locally recurrent, inoperable) relapsing after completed adjuvant Herceptin therapy\n* Indication for first-line treatment with Perjeta in combination with Herceptin and chemotherapy according to the Summary of Product Characteristics\n* Prior Herceptin therapy as systemic adjuvant treatment (postoperative treatment in a potentially curable setting); additional upfront neoadjuvant Herceptin therapy is allowed\n* No prior chemotherapy and/or immunotherapy for advanced (metastatic or locally recurrent, inoperable) HER2-positive breast cancer\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Contraindications to Perjeta, Herceptin or concomitant chemotherapy according to the Summary of Product Characteristics\n* No Herceptin treatment for early breast cancer in the adjuvant setting",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}